Ventafrida V.
è ñîàâò. Comprehhensive treatment in cancer pain managment //
Pain. — 1985. — V. 9. — P. 617 627.
Ventafrida V.
Continuing care: a major issue in cancer pain managment // Pain. —
1989. — V. 36. — P. 137 143.
Veronesi U., Goldhirsch A., Yarnold J.
Breast cancer // In: Oxford Textbook of
Oncology/ Eds. M. Peckham, H. Pinedo, U. Veronesi Oxford University Press. — 1995. —
P. 1241 1292.
Vinholes J., Guo C.Y., Purohit O.P., Eastell R., Coleman R.E.
Metabolic effects of
pamidronate in patients with metastatic bone disease // Br. J. Cancer. — 1996. —V. 73(9). —
P. 1089 1095.
Vinholes J., Guo C.Y., Purohit O.P., Eastell R., Coleman R.E.
Evaluation of new bone
resorption markers in a randomized comparison of pamidronate or clodronate for hyper
calcemia of malignancy // J. Clin. Oncol. — 1997. — V. 15(1). — P.131 138.
Vinholes J., Purohit O.P., Abbey M.E., Eastell R., Coleman R.E.
Relationships
between biochemical and symtomatic response in double blind randomised trial of
pamidronate for metastatic bone disease // Ann. Oncol. — 1997. — V. 8. — P. 1243 1250.
Vinholes J., Coleman R., Lacombe D., Rose C., Tubiana+Hulin M., Bastit P., Wildiers
J., Michel J., Leonard R., Nortier J., Mignolet F., Ford J.
Assessment of bone response to
systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross
link excretion. European Organization for Research and Treatment of Cancer // Br. J.
Cancer. — 1999. — V. 80(1 2). — P. 221 228.
Virotta G., Medolago G., Arrigoni S.
Rhenium 186 HEDP for treatment of painful
metastases from mammary carcinoma // Tumori. — 1997. — V. 83. — P. 563 565.
Vishne T.H., Ron I.G.
Strontium 89 (89Sr) analgesia for rare thymic carcinoid
tumor with bony metastases // Am. J. Clin. Oncol. — 1998. — V. 21(6). — P. 602 604.
Vitte C., Fleisch H., Guenther H.L.
Bisphosphonates induce osteoblasts to secrete an
inhibitor of osteoclast mediated resorption // Endocrinology. — 1996. — V. 137. —
P. 2324 2333.
Vogel C.L., Schoenfelder J., Shemano I., Hayes D.F., Gams R.A.
Worsening bone
scan in the evaluation of antitumor response during hormonal therapy of breast cancer //
J. Clin. Oncol. — 1995. — V. 13(5). — P. 1123 1128.
Zanco P., Rota G., Sportiello V.
Diagnosis of bone and liver metastases in breast can
cer comparing tumor marker and imaging techniques // Int. Biol. Markers. — 1989. —
V. 4 (2). — P. 103 106.
Wachenfeld I., Sanner G., Bottcher H.D., Kollath J.
The remineralization of the ver
tebral metastases of breast carcinoma after radiotherapy // Strahlenther Onkol. — 1996. —
V. 172(6). — P. 332 341.
Wada S., Katayama Y., Yasutomo Y., Kugai N., Nagata N.
Changes of bone meta
bolic markers in patients with bone metastases: clinical significance in assessing bone
response to chemotherapy // Intern. Med. — 1993. — V. 32(8). — P. 611 618.
Wagner W.
Radiotherapy of osseus metastases in breast cancer// Geburtshilfe
Fauenheilkd. — 1991. — V. 51(2). — P. 106 109.
Wakeling A.E., Dukes M., Bowler J.
A potent specific pure antiestrogen with clinical
potential // Cancer Res. –1991. — V.51. — P. 3867 3873.
Walker K., Turkes A., Williams M.
è ñîàâò. Preliminary endocrinological evaluation
of a sustained release formulation of LH releasing hormone agonist in premenopausal
women with advanced breast cancer // J. Endocrin. — 1986. — V. 111. — P. 349 353.
253
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
